Carcinoma of lip

Summary

Carcinoma of lip (MONDO:0021333) is a cancer and 10 clinical trials. Top therapeutic interventions include cisplatin and trastuzumab botidotin. A subtype of lip cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	carcinoma of lip
Mondo ID	MONDO:0021333
NCIT	C3490
SNOMED CT	269515006
UMLS	C0149637
MedGen	56195
GARD	0027894
Anatomy (UBERON)	UBERON:0001833
Is cancer (heuristic)	yes

Also known as: carcinoma of lip · carcinoma of the Lip · lip cancer · lip carcinoma

Disease family

This is a subtype of lip cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › oral cavity cancer › lip cancer › carcinoma of lip

Related subtypes (2): upper lip cancer, lower lip cancer

Subtypes (2): lip carcinoma in situ, squamous cell carcinoma of lip

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03174275	PHASE2	ACTIVE_NOT_RECRUITING	Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
NCT03602079	PHASE1/PHASE2	COMPLETED	Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
NCT00568490	Not specified	RECRUITING	Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
NCT02012699	Not specified	RECRUITING	Integrated Cancer Repository for Cancer Research
NCT05837221	Not specified	RECRUITING	Microbiome in Head and Neck Squamous Cell Carcinoma
NCT00186433	Not specified	COMPLETED	A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
NCT01084733	Not specified	COMPLETED	Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer
NCT04985357	Not specified	WITHDRAWN	Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
NCT05610293	Not specified	UNKNOWN	T1 Squamous Cell Carcinomas of the Lip
NCT07005115	Not specified	COMPLETED	Serum Lipid Profile and Lip Squamous Cell Carcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	1
TRASTUZUMAB BOTIDOTIN	2	1